Ebrahim Mostafavi's research interests at Stanford revolve around the use of cardiac iPS cells to design and develop in vitro models (organoids, vascular grafts, bioengineered tissues) for cardiovascular disease modeling and drug screening as well as CRISPR/Cas gene-editing for cardiovascular diseases. Dr. Mostafavi received his PhD in Chemical Engineering (focusing on Biomedical Engineering and Regenerative Medicine) from Northeastern University, Boston, MA. During his doctoral training, he received several prestigious awards. He has also received training at Harvard Medical School on engineering and development. He has also received training at Harvard Medical School on engineering and developing (nano)biomaterials and 3D scaffolds (hydrogels, 3D bioprinted constructs, and nanoporous scaffolds) to create biologically complex tissues and organs for tissue engineering, regenerative medicine, and translational applications. His scholarly work consists of >80 publications with an H-index of 23 (i10-index= 40) on Google Scholar Profile. He currently serves as the Associate Editor-in-Chief of the International Journal of Nanomedicine (IF=6.4, Q1) at Dove Medical Press/T&F, an Associate Editor of Frontiers in Nanotechnology-Biomedical Nanotechnology, and an Academic Editor-in-Chief of The Innovation, Cell Press. He is also an Editorial Board Member of several biomedical and materials engineering journals, including Nature Scientific Reports (IF=4.379), Springer Nature Journal of Nanostructure in Chemistry (IF=6.39, Q1), MDPI Functional Biomaterials (CiteScore=9.4), MDPI Cells (IF=6.6), BMC Biotechnology (IF=2.563, Q1), BMC Biomedical Engineering, Journal of Medicinal Chemistry (IF=4.53, Q1), Frontiers in Oncology & Frontiers in Pharmacology, etc. He also contributed to more than 15 book chapters and was selected as the editor of several books.